Genetic testing boosts efficacy in cancer care
Tailoring cancer therapies to fit a person's genetic makeup could spare thousands of patients from harmful side effects and save millions of dollars a year, a study shows. Treating a colorectal cancer patient with a drug called Erbitux, for example, costs more than $61,000 for a typical treatment with 24 doses, according to a study presented at the American Society of Clinical Oncology meeting. But over the past year or so, several studies have shown neither Erbitux or Vectibix works in patients with a certain genetic mutation. Giving Erbitux only to patients without the mutations would save the country up to $604 million a year, researchers said.
- Interventional Radiology No Longer a Sub-Specialty
- NFP Hospitals' Revenue Growth at 'All-Time Low'
- Acute Kidney Injury Gets New Focus
- Evidence-Based Practice and Nursing Research: Avoiding Confusion
- Transforming Cancer Care
- Half of All Primary Care, Internal Medicine Jobs Unfilled in 2013
- mHealth Tackles Readmissions
- CNO Leads $1M Charge for New Scrubs, Uniforms
- Proton Beam Therapy Poised for Growth in US
- Sharp HealthCare Leaves Pioneer ACO Program